A regular review of its business practices has led AngioDynamics to restructure its New York operations to focus on product rationalization, lean initiatives, supply chain optimization and enterprise resource planning. The new initiative involves consolidating the company’s operations in that state by manufacturing in Glens Falls and distributing from Queensbury.
The drugmaker is planning to put $5 million to $7 million into the Glens Falls plant, as well as $2 million in one-off charges to expand the distribution capacity of the Queensbury location. Overall, the new streamlined operational plan is intended to save $15 to $18 million over the next three years.
The company also says the consolidation will likely cost the jobs of 80 to 100 employees. — Lena Freund
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.